Immunogenicity as a predictive tool for the response to therapy of high mutation load tumors (IMPRESS)

Project: PN-III-P4-ID-PCE-2016-0870

Estimated results


The results of the present project may allow to create an integrated model for determining which malignant melanoma and non-small cell lung cancer patients may benefit from which therapy, either alone or in combination. The introduction of some predictive algorithms will facilitate the rational development of further clinical trials for application of personalized therapies in patients with poor prognostic cancers such as malignant melanoma and non-small cell lung cancers.